,
Nigoro, Kazuya
Ito, Hiromu https://orcid.org/0000-0002-1827-382X
Kawata, Tomotoshi
Nishitani, Kohei
Tabara, Yasuharu
Matsuda, Fumihiko
Narumiya, Shu
Matsuda, Shuichi
Funding for this research was provided by:
the Ministry of Education, Culture, Sports, Science and Technology of Japan (25293141, 26670313, 26293198, 17H04182, 17H04126, 17H04123, 18K18450)
Japan Agency for Medical Research and Development (ek0109070, ek0109070, ek0109196, ek0109348, dk0207006, dk0207027, kk0205008, ek0210066, ek0210096, ek0210116, le0110005)
Takeda Medical Research Foundation
the Mitsubishi Foundation
the Daiwa Securities Health Foundation
the Sumitomo Foundation
Article History
Received: 14 October 2020
Accepted: 19 November 2020
First Online: 27 November 2020
Ethics approval and consent to participate
: This study was conducted according to the principles of the Declaration of Helsinki and was approved by the ethics committee of Kyoto University Graduate School of Medicine and by the Nagahama Municipal Review Board (No. C278). Written informed consent was obtained from all participants.
: Not applicable
: KaN is an employee of Mitsubishi-Tanabe Pharma. HI belongs to the department which is financially supported by Nagahama City, Shiga, Japan; Toyooka City, Hyogo, Japan; and five pharmaceutical companies (Mitsubishi Tanabe Pharma Co., Chugai Pharmaceutical Co. Ltd., UCB Japan Co. Ltd., Asahi Kasei Pharma Corp., and AYUMI Pharmaceutical Co.). HI also has received a research grant and/or speaker fee from Bristol-Myers Squibb and Eisai. SM has received a research grant and/or speaker fee from Kyocera, Zimmer-Biomet, and Smith&Nephew. TK, KN, YT, FM, and SN declared no conflicts of interest. The sponsors were not involved in the study design; in the collection, analysis, interpretation of data; in the writing of this manuscript; or in the decision to submit the article for publication. The authors, their immediate families, and any research foundations with which they are affiliated have not received any financial payments or other benefits from any commercial entity related to the subject of this article.